BECTON, DICKINSON U.K. LIMITED
The company operates as the UK subsidiary of the NYSE-listed American medical technology group BD, manufacturing medical devices, diagnostic instruments, and clinical supplies.
Get an alert when BECTON, DICKINSON U.K. LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
£776m
-2.5% lowest in 3 filed years
Employees
1,634
-0.7% lowest in 3 filed years
Profit before tax
£47m
+691% highest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Confirmation statement overdue
Due 2026-08-13.
-
Material uncertainty over going concern
The company has net current assets of £120,342,000 (2024: £86,399,000) at the year end and is dependent on the ongoing financial support of its ultimate parent undertaking, Becton, Dickinson and Company, who has confirmed to the directors of the company that this support will continue until 30 June 2027, in order to enable the company to fulfil its financial commitments as and when liabilities fall due.
-
Going-concern uncertainty disclosed
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-09-30
| Metric | Trend | 2023-09-30 | 2024-09-30 | 2025-09-30 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £560,787,000 | £568,470,000 | £589,029,000 | +3.6% | |
| Operating profit | -£123,819,000 | -£6,893,000 | -£21,255,000 | -208.4% | |
| Profit before tax | -£117,034,000 | -£7,881,000 | £46,578,000 | +691% | |
| Net profit | -£118,609,000 | -£9,599,000 | £45,378,000 | +572.7% | |
| Cash | £34,000 | £0 | — | — | |
| Total assets less current liabilities | £889,809,000 | £876,793,000 | £849,641,000 | -3.1% | |
| Net assets | £803,244,000 | £796,181,000 | £776,455,000 | -2.5% | |
| Equity | £803,244,000 | £796,181,000 | £776,455,000 | -2.5% | |
| Average employees | 1,714 | 1,645 | 1,634 | -0.7% | |
| Wages | £105,514,000 | £104,945,000 | £112,201,000 | +6.9% | |
| Directors' remuneration | £1,026,000 | £870,000 | £662,000 | -23.9% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|---|
| Operating margin | -22.1% | -1.2% | -3.6% | |
| Net margin | -21.2% | -1.7% | 7.7% | |
| Return on capital employed | -13.9% | -0.8% | -2.5% | |
| Gearing (liabilities / total assets) | 17.9% | 18.5% | 17.4% | |
| Current ratio | 1.87x | — | — | |
| Interest cover | -22.36x | -1.10x | -6.45x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“The company has net current assets of £120,342,000 (2024: £86,399,000) at the year end and is dependent on the ongoing financial support of its ultimate parent undertaking, Becton, Dickinson and Company, who has confirmed to the directors of the company that this support will continue until 30 June 2027, in order to enable the company to fulfil its financial commitments as and when liabilities fall due.”
Group structure
- BECTON, DICKINSON U.K. LIMITED · parent
- Becton Dickinson Infusion Therapy Holdings UK Limited 100%
- CME UK (Holdings) Limited 54%
- Becton Dickinson Infusion Therapy UK 100%
- Becton Dickinson (CME) U.K. Limited 54%
- Bard Limited 100%
- Bard Sendrian Berhad Malaysia 85%
- KK Medicon, Inc. 50%
- Tissuemed Limited 100%
- Augusta Life Sciences UK Limited 100%
Significant events
- “On 3 September 2024, the company acquired the UK & Ireland Critical Care business and related assets of Edwards Life Sciences, and assumed the associated liabilities, for a total consideration of £10.4 million.”
- “The company has agreed to combine its Biosciences and Diagnostic Solutions businesses with Waters Corporation through a Reverse Morris Trust transaction, under which these businesses will be spun off and merged with a Waters subsidiary.”
- “On 5 February 2025, the company undertook internal reorganisation transactions to facilitate the disposal of its Biosciences (BDB) and Diagnostic Solutions (DS) business units. The disposal was completed on 9 February 2026.”
- “On 22 September 2025, the company acquired 100% of the voting shares of Augusta Life Sciences UK Limited for £1.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 18 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| GREEN, Robert John, Mr. | Director | 2022-12-21 | Jun 1973 | British |
| THOMAS, Glenn Michael, Mr. | Director | 2023-07-18 | May 1987 | British |
| WAKEFIELD, Ian Kurt | Director | 2026-05-01 | Jul 1965 | South African |
Show 18 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ARNOLD, Julie Christine | Secretary | — | 2008-01-08 |
| NEYLON, Anthony | Secretary | 2008-01-08 | 2015-07-09 |
| ADAMS, Alex, Country General Manager | Director | 2008-10-01 | 2015-07-09 |
| ARNOLD, Julie Christine | Director | — | 2017-02-16 |
| BAILLIE, Ruth | Director | 2000-11-01 | 2007-03-23 |
| BERMAN, Richard Kenneth | Director | 2009-03-19 | 2012-01-23 |
| ELSEY, Keith Anthony Lambert | Director | — | 2000-05-17 |
| FAIRBOURN, Michael John | Director | 2015-07-09 | 2025-12-05 |
| GIBSON, Kathleen | Director | 2001-12-11 | 2002-09-16 |
| HANSON, Alfred John | Director | — | 2007-09-30 |
| HEALY, Bridget | Director | 1999-10-01 | 2003-11-19 |
| HOPKIN, Edward Daniel | Director | 2015-02-02 | 2022-12-21 |
| LUNDGREN, Johnny | Director | 2011-06-28 | 2015-02-02 |
| LUNDGREN, Johnny | Director | 2007-02-26 | 2008-10-01 |
| NEAT, John Konrad | Director | 2015-07-09 | 2024-05-10 |
| NEYLON, Anthony | Director | 2007-02-26 | 2015-07-09 |
| THOMPSON, Stephen Russel | Director | — | 2000-04-06 |
| VENKATARAMAN, Srividhya | Director | 2019-11-05 | 2023-02-02 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Bard Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-09-21 | Active |
| Becton Dickinson And Company | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2017-09-11 | Ceased 2019-09-21 |
| Bd Uk Holdings Ltd | Corporate entity | Shares 75–100% | 2016-04-06 | Ceased 2017-09-11 |
Filing timeline
Last 20 of 170 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-10 | AA | accounts | Accounts with accounts type full | |
| 2026-05-06 | AP01 | officers | Appoint person director company with name date | |
| 2025-12-11 | TM01 | officers | Termination director company with name termination date | |
| 2025-07-31 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-04-22 | AA | accounts | Accounts with accounts type full | |
| 2025-04-16 | AD03 | address | Move registers to sail company with new address | |
| 2025-04-16 | AD02 | address | Change sail address company with new address | |
| 2024-08-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-06-07 | TM01 | officers | Termination director company with name termination date | |
| 2024-04-16 | AA | accounts | Accounts with accounts type full | |
| 2023-08-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-24 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-26 | AA | accounts | Accounts with accounts type full | |
| 2023-02-03 | TM01 | officers | Termination director company with name termination date | |
| 2023-01-19 | AP01 | officers | Appoint person director company with name date | |
| 2023-01-19 | TM01 | officers | Termination director company with name termination date | |
| 2022-08-15 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-07-14 | SH01 | capital | Capital allotment shares | |
| 2022-06-15 | AA | accounts | Accounts with accounts type full | |
| 2021-09-06 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.